Ken Fisher Fisher Asset Management
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$951M |
| 2 |
Advanced Micro Devices
AMD
|
+$589M |
| 3 |
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
|
+$418M |
| 4 |
Lam Research
LRCX
|
+$412M |
| 5 |
Microsoft
MSFT
|
+$207M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$1.24B |
| 2 |
Apple
AAPL
|
+$585M |
| 3 |
STMP
Stamps.com, Inc.
STMP
|
+$111M |
| 4 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
+$87.8M |
| 5 |
TSMC
TSM
|
+$70.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.05% |
| 2 | Financials | 11.79% |
| 3 | Healthcare | 10.9% |
| 4 | Consumer Discretionary | 10.36% |
| 5 | Communication Services | 8.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
DexCom
DXCM
$31.3B
| $29.6M | 0.02% |
216,332
-492
| -0.2% | -$62K |
|
252
TG Therapeutics
TGTX
$7.59B
| $29.4M | 0.02% |
882,441
+430,385
| +95% | +$13.3M |
|
253
Rogers Corp
ROG
$2.39B
| $28.6M | 0.02% |
153,135
-5,652
| -4% | -$1.11M |
|
|
COR
254
DELISTED
Coresite Realty Corporation
COR
| $28.2M | 0.02% |
203,809
-5,576
| -3% | -$796K |
|
255
Cummins
CMI
$88.7B
| $28.1M | 0.02% |
125,301
+1,467
| +1% | +$344K |
|
256
Shopify
SHOP
$191B
| $28M | 0.02% |
206,700
+50,630
| +32% | +$7.59M |
|
257
Glacier Bancorp
GBCI
$6.32B
| $27M | 0.02% |
488,334
-14,369
| -3% | -$756K |
|
|
CONE
258
DELISTED
CyrusOne Inc Common Stock
CONE
| $26.8M | 0.02% |
345,694
-9,659
| -3% | -$726K |
|
259
BridgeBio Pharma
BBIO
$16.2B
| $26.7M | 0.02% |
+569,265
| New | +$30.5M |
|
260
Emergent Biosolutions
EBS
$274M
| $26.5M | 0.02% |
528,836
+33,419
| +7% | +$2.02M |
|
261
Sony
SONY
$136B
| $26.3M | 0.02% |
+1,188,445
| New | +$24.9M |
|
262
ENI
E
$78.6B
| $26.2M | 0.02% |
977,938
-3,034
| -0.3% | -$74K |
|
263
IPG Photonics
IPGP
$3.69B
| $26.1M | 0.02% |
164,907
+13,958
| +9% | +$2.56M |
|
264
Helmerich & Payne
HP
$3.7B
| $25.6M | 0.02% |
935,153
-164,464
| -15% | -$4.59M |
|
265
Marvell Technology
MRVL
$189B
| $25.2M | 0.02% |
417,424
+88,361
| +27% | +$5.3M |
|
266
Nucor
NUE
$61.9B
| $24.5M | 0.02% |
248,504
+43,022
| +21% | +$4.57M |
|
267
Kennametal
KMT
$2.58B
| $24.2M | 0.02% |
708,375
-10,470
| -1% | -$376K |
|
268
WillScot Mobile Mini Holdings
WSC
$4.67B
| $24.2M | 0.02% |
762,161
+593
| +0.1% | +$17.1K |
|
|
CADE
269
DELISTED
Cadence Bank
CADE
| $24M | 0.01% |
805,970
-26,013
| -3% | -$725K |
|
|
NVTA
270
DELISTED
Invitae Corporation
NVTA
| $23.7M | 0.01% |
+833,946
| New | +$24.4M |
|
|
SWAV
271
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $23.7M | 0.01% |
114,919
+29,869
| +35% | +$5.86M |
|
|
FRC
272
DELISTED
First Republic Bank
FRC
| $23.4M | 0.01% |
121,447
+10,077
| +9% | +$1.98M |
|
|
GTHX
273
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $23.3M | 0.01% |
1,738,211
+823,373
| +90% | +$13.4M |
|
274
Oceaneering
OII
$4.9B
| $22.9M | 0.01% |
1,722,928
-509,892
| -23% | -$6.65M |
|
275
Ziff Davis
ZD
$1.88B
| $22.9M | 0.01% |
192,766
-248
| -0.1% | -$29.8K |
|
Similar funds
Ken Fisher's Q3 2021 Portfolio in Review
As of Q3 2021, Ken Fisher held 1,103 positions worth $161B, up 1.1% from $159B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Ken Fisher's Q3 2021 filing shows 93 new, 444 increased, 375 reduced and 75 closed positions. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 267,976 shares worth $37.2M. The largest sale was Visa, an estimated $1.24B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 26% a quarter earlier, followed by Financials and Healthcare.
- Ken Fisher's largest Q3 2021 buy was Biohaven Pharmaceutical Holding Company Ltd.: 267,976 shares worth $37.2M.
- Ken Fisher added most to Meta Platforms (Facebook) in Q3 2021, an estimated $951M increase.
- Ken Fisher's biggest Q3 2021 reduction was Visa, cutting an estimated $1.24B.
- Ken Fisher fully exited Stamps.com, Inc. in Q3 2021, selling an estimated $111M.
- Ken Fisher's ten largest holdings make up 31% of its $161B portfolio in Q3 2021.
- Ken Fisher opened 93 new positions and closed 75 in Q3 2021.
- Ken Fisher's portfolio value rose 1.1% quarter-over-quarter to $161B.
Based on Fisher Asset Management's 13F filing for Q3 2021, filed 26 Oct 2021.